Open Label Extension Study of AMG 531 in Japanese Subjects With ITP
An Open Label Extension Study Evaluating the Safety and Efficacy of Long Term Dosing of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Sponsor: Kyowa Kirin Co., Ltd.
This PHASE2/PHASE3 trial investigates Immune (Idiopathic) Thrombocytopenic Purpura (ITP) and is currently completed. Kyowa Kirin Co., Ltd. leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 4 earlier versions
-
Aug 2019 — Feb 2020 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Nov 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Kirin Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Chūō, Japan , Hirakata, Japan , Hiroshima, Japan , Isehara-shi, Japan , Kumamoto, Japan , Moriguchi, Japan , Sagamihara, Japan , Sapporo, Japan , Suita, Japan , Tokyo, Japan and 1 more location